Literature DB >> 6382569

Immunocytochemical distribution of trypsinogen and pancreatic secretory trypsin inhibitor in normal and neoplastic tissues in man.

W H Marks, K Ohlsson, A Polling.   

Abstract

Immunoreactive trypsinogen and pancreatic secretory trypsin inhibitor (PSTI) were demonstrated in pancreas by means of an immunoperoxidase technique. They had the same distribution in acinar cells of 'normal' human exocrine pancreas tissues. Ductal adenocarcinoma tissue and pancreatic undifferentiated carcinoma contained neither antigen. Scattered 'normal'-looking cells in the border area between normal and neoplastic tissue of both types of tumor stained positively for trypsinogen and for PSTI.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6382569

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

Review 1.  Genetic risk factors for pancreatic disorders.

Authors:  David C Whitcomb
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

2.  Absence of trypsinogen autoactivation and immunolocalization of pancreatic secretory trypsin inhibitor in acinar cells in vitro.

Authors:  A E Arias; T Böldicke; M Bendayan
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

3.  Varying occurrence of gastroduodenal immunoreactive pancreatic secretory trypsin inhibitor.

Authors:  M Bohe; C G Lindström; K Ohlsson
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

4.  Elevated serum levels of immunoreactive anionic trypsin (but not cationic trypsin) signals pancreatic disease.

Authors:  A Borgström; A Andrén-Sandberg
Journal:  Int J Pancreatol       Date:  1995-12

5.  Appearance mechanism and molecular heterogeneity of serum pancreatic secretory trypsin inhibitor (PSTI).

Authors:  I Nakano; A Funakoshi; T Sumii; K Miyazaki; Y Oogami; T Kimura; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1985-08

6.  Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions.

Authors:  T Ohta; T Terada; T Nagakawa; H Tajima; H Itoh; L Fonseca; I Miyazaki
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

7.  Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.

Authors:  C Haglund; M L Huhtala; H Halila; S Nordling; P J Roberts; T M Scheinin; U H Stenman
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

8.  Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy.

Authors:  Sumit Sahni; Christopher Nahm; Christoph Krisp; Mark P Molloy; Shreya Mehta; Sarah Maloney; Malinda Itchins; Nick Pavlakis; Stephen Clarke; David Chan; Anthony J Gill; Viive M Howell; Jaswinder Samra; Anubhav Mittal
Journal:  Front Oncol       Date:  2020-03-04       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.